Welcome to the homepage of LBI-HTA !
The LBI-HTA is an acadmic non-profit institute and belongs to the Ludwig Boltzmann Society. At our website we wish to present our research and give support for health care decision-making. Here all of our reports are available for free. For further information please contact the LBI-HTA team.
Prevalence of mental disorders and uptake of mental health services in Tyrol: An analysis of epidemiological literature and administrative data from the Tyrolean health insurance
A recently started 4-year research project aims at improving the situation of children who have mentally ill parents in Tyrol. Different approaches can be followed for early identifying and supporting these children. One is to get into contact with the children via the parents in the adult mental health care settings. To explore this strategy further, we analysed the prevalence of mental disorders and the use of mental health benefits that are provided within the health care sector in Tyrol. Our data sources were published literature and administrative data from the Tyrolean health insurance.
Publication: LBI-HTA Project report No. 103b: http://eprints.hta.lbg.ac.at/1181/
Contact: Ingrid Zechmeister-Koss
Supporting children who have parents with mental disorders in Tyrol: A mapping of existing Tyrolean support and societal structures
A recently started 4-year research project aims at improving the situation of children who have mentally ill parents in Tyrol. For developing practice approaches to better identify and support these children and their parents, we need an in-depth understanding of the regional Tyrolean characteristics in terms of existing support structures and the societal context they are embedded in. The report gives an overview on the socio-economic and demographic context in Tyrol and describes available in-kind and cash-benefits that may play a role in improving identifying and supporting the children and their families.
Publication: LBI-HTA Project report No. 103a: http://eprints.hta.lbg.ac.at/1180/
Contact: Ingrid Zechmeister-Koss
Hardly any other medical technology has been evaluated as often in the western countries as positron emission tomography (PET/PET-CT): this is an expression of uncertainty about the value of PET diagnostics in the care of patients. The present HTA report updates the evidence on oncological indications and adds neurological indications and inflammatory diseases to the LBI-HTA report from 2015. The report was conducted in cooperation between the TU Berlin and the LBI-HTA to provide an updated decision support for evidence-based PET/PET-CT planning in Germany and Austria.
Publication: LBI-HTA Project report No. 77/ Update: http://eprints.hta.lbg.ac.at/1178/
This Information is available in German only.
External stimulation of the trigeminal nerve for the prevention and acute treatment of episodic and chronic migraine
External trigeminal nerve stimulation (e-TNS) device produced by the manufacturer Cefaly is the intervention at stake. The mechanism of action is that e-TNS produces a micro-pulse on the upper branch of the trigeminal nerve (suborbital nerve) through an adhesive electrode that is placed on the forehead. The aim of the project is to perform a synthesis of evidence on the basis of a systematic literature search regarding effectiveness and safety of the e-TNS for the prevention and treatment of episodic and chronic migraine.
Publication: Decision Support Document No. 114: http://eprints.hta.lbg.ac.at/1177/
Contact: Michal Stanak
We are pleased to introduce our two new HSO reports.
Carbon ion beam radiotherapy (CIRT) for cancer treatment: a systematic review of effectiveness and safety for 12 oncologic indications.
The project aimed at elaborating possible cancer types, being an indication for carbon ion radiotherapy (CIRT). As such, clinical studies, analysing the use of CIRT for specific cancer types, were identified through a systematic literature search and were reviewed and reported in this project.
Furthermore, a systematic review on the effectiveness (mortality, morbidity) and safety of CIRT for 54 oncologic indications in 12 regions (i.e., skull base, eye, brain, ear-nose-throat, lung, gastrointestinal, bone and soft tissue, prostate, breast, kidney, nervous system, hematologic cancer) was conducted.
Publication: LBI-HTA Project report No. 101: http://eprints.hta.lbg.ac.at/1174/
Contact: Gregor Goetz